Physician‑Guided · HIPAA Compliant · Discreetly Delivered Nationwide
Dual GIP/GLP-1 Therapy · Physician-Supervised
Mounjaro®
The first medication to activate both GIP and GLP-1 receptors simultaneously — a dual-agonist approach that produced unprecedented metabolic outcomes in clinical trials.
You will be directed to our licensed telehealth partner to complete your consultation.
Mounjaro® (tirzepatide) represents a new pharmacological category: the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating two distinct incretin receptor pathways simultaneously, tirzepatide produced metabolic outcomes in clinical trials that exceeded anything previously observed with single-receptor GLP-1 therapies. Through The Project Rx and our licensed telehealth partner, patients can access a comprehensive consultation with a licensed provider to explore whether Mounjaro® may be clinically appropriate for them.
What Is Mounjaro®?
Mounjaro® is the brand name for tirzepatide, a once-weekly injectable medication developed by Eli Lilly and Company. It received FDA approval in May 2022 for the treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise — making it the first approved dual GIP and GLP-1 receptor agonist in the world.
The significance of tirzepatide's dual mechanism is substantial. Prior to its development, the two most effective metabolic intervention pathways — GIP receptor activation and GLP-1 receptor activation — had never been combined into a single pharmaceutical agent. The scientific hypothesis was that combining these two incretin pathways might produce additive or even synergistic metabolic effects. The SURPASS clinical trial program confirmed this hypothesis with remarkable results.
Tirzepatide is a synthetic peptide that has been engineered to activate both GIP and GLP-1 receptors with high affinity and specificity. It is administered once weekly via a subcutaneous injection using a single-dose pen. The medication is available at five doses — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — and patients typically begin at the lowest dose and titrate upward every four weeks based on response and tolerability.
While Mounjaro® is currently FDA-approved for type 2 diabetes, the weight reduction observed in the SURPASS trials and subsequently in the SURMOUNT trials (which used tirzepatide to study obesity directly — that data supports the Zepbound® formulation) established tirzepatide as one of the most powerful metabolic agents studied to date. Prescribing decisions for Mounjaro® are made by licensed providers based on each patient's individual clinical situation.
2022
Year of FDA approval for type 2 diabetes management
Dual
Receptor mechanism — both GIP and GLP-1 agonism simultaneously
Up to 15 mg
Maximum weekly dose after stepwise titration
Mechanism of Action
How Mounjaro® Works
What makes tirzepatide uniquely powerful is its dual-agonist mechanism. Most GLP-1 receptor agonists — including semaglutide — act on a single receptor pathway. Tirzepatide activates two: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. This dual activity is why tirzepatide is sometimes referred to in scientific literature as a "twincretin."
GIP is an incretin hormone secreted by K-cells in the small intestine in response to nutrient absorption. Like GLP-1, GIP stimulates insulin secretion from the pancreas in a glucose-dependent manner. However, GIP also has direct effects on adipose tissue (fat cells), acting on GIP receptors to influence fat storage and mobilization. Animal studies and early human data suggest that GIP receptor activation in the brain may also contribute to appetite regulation — though GIP's central actions are less well characterized than GLP-1's.
The GLP-1 component of tirzepatide produces effects familiar from other GLP-1 agents: slowed gastric emptying, appetite suppression via hypothalamic pathways, glucose-dependent insulin release, and glucagon suppression. When GIP and GLP-1 receptor activations are combined, these effects appear to work together — reducing appetite signals more profoundly, improving insulin sensitivity more substantially, and producing greater reductions in body weight than either pathway achieved alone in comparable trials.
The SURPASS-2 trial — which directly compared tirzepatide against semaglutide 1 mg (the leading approved dose at the time) — demonstrated superior outcomes on every measured endpoint: HbA1c reduction, body weight, fasting glucose, and more. This head-to-head superiority to the leading GLP-1 agent was a landmark result in metabolic pharmacology.
GIP Receptor Activation
Tirzepatide activates GIP receptors in the pancreas, adipose tissue, and potentially the brain — producing insulin sensitization and fat metabolism effects distinct from GLP-1 receptor agonism alone.
GLP-1 Receptor Activation
Simultaneous GLP-1 activation suppresses appetite via hypothalamic pathways, slows gastric emptying, suppresses glucagon, and promotes glucose-dependent insulin release.
Synergistic Dual-Pathway Effect
The combination of both receptor pathways appears to produce additive-to-synergistic metabolic benefits — with clinical trial data showing outcomes exceeding those of leading single-receptor GLP-1 agents.
Candidacy
Who May Be a Candidate
Mounjaro® is FDA-approved for adults with type 2 diabetes mellitus as an adjunct to diet and exercise. As with all prescription medications, the determination of whether tirzepatide is clinically appropriate for a specific patient requires a thorough evaluation by a licensed medical provider.
During the telehealth consultation facilitated by The Project Rx, your provider will review your medical history, current medications and supplements, metabolic lab values, and health goals. Patients with established type 2 diabetes seeking optimized glycemic control or those with elevated metabolic risk factors may be candidates for this evaluation. Licensed providers may also consider clinical factors beyond the FDA's stated indication based on their professional judgment and your individual presentation.
It is worth noting that tirzepatide in its formulation as Zepbound® — a separate FDA-approved product by the same manufacturer — is specifically indicated for chronic weight management in adults with obesity or overweight. If your primary goal is weight management rather than diabetes management, your provider may discuss which formulation is most appropriate for your situation.
All prescribing decisions are made solely by licensed medical professionals. The Project Rx facilitates access to the consultation; we do not evaluate eligibility, prescribe medications, or dispense pharmaceuticals.
May Be Appropriate If
- ›Adults with type 2 diabetes seeking improved glycemic control
- ›Patients on existing diabetes therapy considering a GLP-1/GIP combination option
- ›Adults with metabolic syndrome and elevated cardiovascular risk
- ›Patients where weight reduction is a secondary but clinically meaningful goal
- ›No personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- ›No current or recent history of pancreatitis
Not Typically Appropriate If
- —Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
- —Type 1 diabetes (not indicated)
- —Pregnancy or planning to become pregnant
- —History of serious hypersensitivity to tirzepatide
- —Active pancreatitis
Dosing Overview
Titration Schedule
Mounjaro® is initiated at 2.5 mg weekly and titrated upward in 2.5 mg increments every four weeks. The titration schedule reflects the need to allow the gastrointestinal system to adapt to the medication's effects — particularly the slowing of gastric emptying — before advancing to higher doses.
The 2.5 mg starting dose is considered a tolerability dose rather than a full therapeutic dose for glycemic control. Most patients begin to experience meaningful glycemic and appetite effects at 5 mg and above. The target maintenance dose varies by patient and is determined by your prescribing provider based on response, tolerability, and clinical goals.
Not all patients advance to the 15 mg maximum dose — many achieve excellent outcomes at 5 mg, 7.5 mg, or 10 mg, and there is no clinical requirement to advance to the highest dose if therapeutic goals are achieved at lower levels. Dose decisions should always be made in consultation with your licensed provider.
Injections are administered once weekly into the abdomen, thigh, or upper arm. The injection day should remain consistent each week, though the time of day can vary. If you miss a dose by fewer than four days, administer it as soon as you remember. If more than four days have passed, skip the missed dose and resume your regular schedule.
Weeks 1–4
Initiation — tolerability phase
2.5 mg/week
Weeks 5–8
First therapeutic maintenance dose option
5 mg/week
Weeks 9–12
Continued escalation if needed
7.5 mg/week
Weeks 13–16
Continued escalation if needed
10 mg/week
Weeks 17–20
Higher-dose option
12.5 mg/week
Week 21+
Maximum dose — if additional benefit needed
15 mg/week
* Dose adjustments are determined by your prescribing provider based on response and tolerability. Not all patients advance to higher doses.
Clinical Evidence
What the Research Shows
−2.3%
Superior HbA1c reduction vs. semaglutide 1 mg at 15 mg dose
SURPASS-2
−12.4 kg
Average weight loss at 15 mg dose vs. −6.2 kg for semaglutide
SURPASS-2, 40 weeks
~90%
Of patients at 15 mg achieved HbA1c below 7.0% target
SURPASS-2
The SURPASS clinical trial program consisted of five Phase 3 randomized controlled trials enrolling adults with type 2 diabetes at varying stages of treatment. Across all five trials, tirzepatide demonstrated superior glycemic control compared to active comparators — including insulin glargine, semaglutide 1 mg, and insulin degludec — while also producing substantial reductions in body weight.
SURPASS-2 is perhaps the most clinically significant trial in terms of comparison: it directly randomized patients to tirzepatide (5, 10, or 15 mg) versus semaglutide 1 mg. All three tirzepatide doses achieved superior HbA1c reductions, and tirzepatide at 10 mg and 15 mg achieved significantly greater weight reductions than semaglutide 1 mg over 40 weeks. This was the first head-to-head demonstration of a dual GIP/GLP-1 agent outperforming a leading GLP-1 agent in a randomized controlled trial.
SURPASS-4 and SURPASS-5 evaluated tirzepatide against basal insulin in patients with more advanced diabetes, demonstrating both superior glycemic control and weight reduction compared to insulin therapy — notable findings for a population where insulin typically causes weight gain rather than loss.
For weight management specifically, the SURMOUNT trials studied tirzepatide in patients without type 2 diabetes and demonstrated average weight reductions of approximately 20–22% over 72 weeks at the 15 mg dose — results that have redefined the expectations for pharmacological weight management.
Safety Information
Side Effects & Risks
The side effect profile of Mounjaro® is broadly similar to that of GLP-1 receptor agonists, with gastrointestinal effects being the most common. The addition of GIP receptor activity has not been shown to substantially increase the rate of GI side effects compared to semaglutide in head-to-head comparisons. However, at higher doses (10 mg, 12.5 mg, 15 mg), GI effects may be more pronounced.
In the SURPASS trials, nausea was reported in approximately 17–22% of patients depending on dose, compared to approximately 14% with semaglutide 1 mg in SURPASS-2. The majority of events were mild to moderate and occurred predominantly during dose escalation. Approximately 5–6% of patients discontinued tirzepatide due to GI side effects.
Practical management of GI side effects follows similar principles to other GLP-1 therapies: slower dose escalation when needed, dietary modifications (smaller meals, lower fat intake), adequate hydration, and avoidance of lying down immediately after eating. Your licensed provider can adjust the titration schedule if you experience significant GI side effects.
Common (≥1 in 10)
- · Nausea (most common — dose-dependent, often peaks during escalation)
- · Diarrhea
- · Decreased appetite
- · Vomiting
- · Constipation
- · Abdominal pain / discomfort
- · Dyspepsia / reflux
Serious Risks (Discuss with Provider)
- · Pancreatitis (discontinue immediately if suspected)
- · Thyroid C-cell tumors (rodent carcinogenicity data; contraindicated in MTC/MEN2 history)
- · Hypoglycemia (particularly in combination with insulin or sulfonylureas)
- · Gallbladder disease (particularly with rapid weight loss)
- · Acute kidney injury (with dehydration from GI events)
- · Serious hypersensitivity reactions (rare)
Patients taking Mounjaro® concurrently with insulin or insulin secretagogues (such as sulfonylureas) face an increased risk of hypoglycemia. Dose adjustments of those medications may be needed. This is a critical safety consideration to discuss with your prescribing provider before initiating tirzepatide. This is not a complete side effect summary — review the full FDA prescribing information with your provider.
How It Works
The Consultation Process
The Project Rx facilitates access to a licensed telehealth consultation through LegUp Health, whose network of licensed providers can evaluate your candidacy for Mounjaro®, order labs if needed, and issue prescriptions through licensed pharmacies for clinically eligible patients.
The process is streamlined, entirely online, and HIPAA-compliant. Licensed providers in the network have experience in metabolic medicine and diabetes management and are equipped to conduct thorough evaluations of tirzepatide candidacy. The following outlines the typical journey from initial inquiry through ongoing care.
Health Intake Form
Complete a comprehensive intake covering your type 2 diabetes history, current medications (including all diabetes medications), metabolic labs, and health goals. Precision here improves the quality of your consultation.
Provider Consultation
A licensed provider reviews your intake and conducts a telehealth consultation to assess candidacy for tirzepatide, discuss the dual GIP/GLP-1 mechanism, and review options including dosing approach and monitoring plan.
Lab Review or Ordering
Existing labs are reviewed or new labs ordered. For diabetes management, HbA1c, kidney function, liver function, and baseline metabolic panel are standard. Thyroid evaluation may be conducted if relevant.
Prescription Issuance
If clinically appropriate, your provider issues a prescription for Mounjaro®. Insurance prior authorization support is available, and Eli Lilly's savings programs are discussed for eligible patients.
Follow-Up & Dose Titration
Ongoing follow-up consultations ensure safe dose titration, side effect management, and monitoring of glycemic and metabolic markers. Tirzepatide requires regular provider oversight, especially during the escalation phase.
What to Expect
Month-by-Month Overview
Tirzepatide's clinical effects accumulate gradually over weeks and months. The SURPASS trials tracked participants for 40–52 weeks for their primary endpoints, with meaningful effects on both glycemic control and body weight observed throughout the study duration. The following overview reflects typical patterns — individual responses vary.
GI side effects are most prominent during dose escalation and typically diminish at each stable dose level. Glycemic improvements often become measurable before significant weight changes are apparent. Weight reduction, when it occurs, typically accelerates in the mid-treatment period (months 3–6) as dose levels increase and appetite suppression deepens.
Initiation & First Dose Increase
Starting at 2.5 mg and advancing to 5 mg. GI adjustment period — nausea may occur, particularly around the 5 mg transition. Early appetite changes common. Glycemic markers may begin shifting modestly.
Therapeutic Range Entry
Advancing through 7.5–10 mg doses. More substantive HbA1c reductions become measurable. Appetite suppression often deepens notably. Weight changes, when occurring, become more consistent and measurable.
Higher Doses & Accelerated Benefit
Reaching 12.5–15 mg range for patients continuing escalation. In SURPASS-2, the most significant separation from comparator occurred in months 4–8. Weight reductions continue accumulating. GI side effects typically stable at established doses.
Long-Term Metabolic Management
At stable doses, both glycemic and weight effects are maintained with continued dosing. In SURPASS trials, improvements were durable through 40–52 weeks. Regular monitoring of HbA1c, kidney function, and metabolic markers continues.
FAQ
Frequently Asked Questions
Access & Pricing
Starting at $1,069/month
Medication cost is an estimate based on current market pricing without insurance coverage. Insurance coverage varies significantly by plan and indication. Eli Lilly offers savings programs for eligible patients.
Begin Your ConsultationEligibility is determined by a licensed provider following your consultation. Not all patients qualify for a prescription.
Mounjaro® is a registered trademark of Eli Lilly and Company. The Project Rx is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. Brand names appearing on this page are used solely for informational identification of the referenced medications. The Project Rx facilitates access to licensed telehealth consultations; we do not manufacture, sell, or dispense prescription medications. All prescription decisions are made exclusively by licensed medical professionals following a clinical evaluation. This content is for informational purposes only and does not constitute medical advice.